32 DAYS TO SARS-CoV-2 HUMAN ANTIBODY
Prellis Bio announces that it has generated 300 human antibodies that have neutralization potential against SARS-CoV-2.
Prellis Biologics began the process of rapid fully human antibodies to SARS-CoV-2 in April of 2020. Human antibodies can conferring temporary immunity and prophylactic treatment options making them a valuable tool in the fight against COVID-19.
Synthetic lymph nodes leverage real human immune responses to rapidly (32 days) produce novel human antibodies for production. The process does not require human infection or massive screening libraries. The surrogate human immune system preselects and produces antibodies that can be immediately tested for therapeutic efficacy and scaled for Phase I/II clinical trial use; thus leveraging existing antibody production technologies.